Estrogen and the treatment of Alzheimer's disease

American Journal of Medicine

Volumn 103, Issue 3 A, 1997, Pages 36S-45S

  Birge, Stanley J ^a,b   Mortel, Karl F ^a,b  

^a Older Adult Health Center   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; APOLIPOPROTEIN E4; ASCORBIC ACID; CHOLESTEROL; CONJUGATED ESTROGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTRADIOL; ESTRADIOL BENZOATE; ESTROGEN; INDOMETACIN; KETOPROFEN; MEDROXYPROGESTERONE; MEVINOLIN; NONSTEROID ANTIINFLAMMATORY AGENT; PENTOXIFYLLINE; PLACEBO; PRAVASTATIN; PROSTAGLANDIN SYNTHASE INHIBITOR; SELEGILINE; TESTOSTERONE;

AGING; ALZHEIMER DISEASE; BRAIN BLOOD FLOW; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; ESTROGEN THERAPY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; MULTIINFARCT DEMENTIA; OXIDATIVE STRESS; PRIORITY JOURNAL; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0030860139     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(97)00258-1     Document Type: Conference Paper

References (97)

1. Plassman BL, Breitner JCS. Recent advances in the genetics of Alzheimer's disease and vascular dementia with an emphasis on gene-environment interactions. JAGS. 44:1996;1242-1250.
2. Breitner JCS, Welsh KA, Gau BA, et al. Alzheimer's disease in the National Academy of Science National Research Council Registry of Aging twin veterans. III. Detection of cases, longitudinal results, and observations on twin concordance. Arch Neurol. 52:1995;763-771.
3. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 240:1988;622-630.
4. Boyles JK, Zoellner CD, Anderson LJ, Kosik LM, Pitas RE, Weisgraber KH, Hui DY, Mahley RW, Gebicke-Haerter PJ, Ignatius MJ, Shooter EM. A role for apolipoprotein E, apolipoprotein E, apolipoprotein A-1, and low density lipoprotein receptors in cholesterol transport during regeneration and remyelination of the rat sciatic nerve. J Clin Invest. 83:1989;1015-1031.
5. Boyles JK, Notterpek LM, Anderson LJ. Accumulation of apolipoproteins in the regenerating and remyelinating mammalian peripheral nerve. J Biol Chem. 265:1990;17805-17815.
6. Poirier J, Hess M, May PC, Finch CE. Astrocytic apolipoprotein E mRNA and GFAP mRNA in hippocampus after entorhinal cortex lesioning. Molec Brain Res. 11:1991;97-106.
7. Holtzman DM, Pitas RE, Kilbridge J. Low density lipoprotein receptor related protein mediates apolipoprotein E-dependent neurite outgrowth in a central nervous system derived neuronal cell line. Neurobiology. 92:1995;9480-9484.
8. Mayeux R, Ottman R, Maestre G, et al. Synergistic effects of traumatic head injury and apolipoprotein-epsilon 4 in patients with Alzheimer's disease. Neurology. 45:1995;555-557.
9. Hebert LE, Scherr PA, Beckett LA, et al. Age-specific incidence of Alzheimer's disease in a community population. JAMA. 273:1995;1354-1359.
10. Jorm AF, Korten AE, Henderson AS. The prevalence of dementia in quantitative integration of the literature. Acta Psychiatr Scand. 76:1987;465-479.
11. Morris JC, Storandt M, McKeel DW, et al. Cerebral amyloid deposition and diffuse plaques in "normal" aging: evidence for presymptomatic and very mild Alzheimer's disease. Neurology. 46:1996;707-719.
12. Price JL, Davis PB, Morris JC, White DL. The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiol Aging. 12:1991;295-312.
13. Hara H, Kato H, Kogure K. Protective effect of alpha-tocopherol on ischemic neuronal damage in the gerbil hippocampus. Rain Res. 510:1990;335-338.
14. Behl C, Davis J, Cole GM, Schubert D. Vitamin E protects nerve cells from amyloid-beta protein toxicity. Biochem Biophys Res Commun. 186:1992;944-950.
15. Losonczy K, Harris TB, Havlik RJ. Vitamin E and vitamin C supplement use and risk of all-cause and coronary heart disease in older persons: the established populations for epidemiologic studies of the elderly. Am J Clin Nutr. 64:1996;190-196.
16. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med. 336:17:1997;1216-1222.
17. Skoog I, Nilsson L, Palmertz B, Andreasson L-A, Svanborg A. A population-based study of dementia in 85-year-olds. N Engl J Med. 328:1993;153-158.
18. Ferrucci L, Guralnik JM, Salive ME, et al. Cognitive impairment and risk of stroke in the older population. JAGS. 44:1996;237-241.
19. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 43:1993;250-260.
20. Erkinjuntti T, Hachinski VC. Rethinking vascular dementia. Cerebrovasc Dis. 3:1993;3-23.
21. Krishman KRR, Gadde KM. The pathophysiologic basis for late-life depression. Imaging studies of the aging brain. Am J Ger Psychiatry. 4:(suppl 1):1996;S22-S33.
22. Boone KB, Miller BL, Lesser IM, et al. Neuro-psychological correlates of white matter lesions in healthy elderly subjects. Arch Neurol. 49:1992;549-554.
23. Schmidt R, Fazekas F, Offenbacher H, et al. Neuro-psychologic correlates of MRI white matter hyperintensities: a study of 150 normal volunteers. Neurology. 43:1993;2490-2494.
24. Fazekas F, Niederkorn K, Schmidt R, et al. White matter signal abnormalities in normal individuals. Stroke. 19:1988;1285-1288.
25. Awad IA, Spetzler RF, Hodak JA, Awad CA, Carey R. Incidental subcortical lesions identified on magnetic resonance imaging in the elderly. Stroke. 17:1986;1084-1089.
26. Abe K, Tanzi RE, Kogure K. Selective induction of Kunitz-type protease inhibitor domain-containing amyloid precursor protein mRNA after persistent focal ischemia in rat cerebral cortex. Neurosci Lett. 125:1991;172-174.
27. Frisoni GB, Calabresi L, Geroldi C. Apolipoprotein E ApoE 4 allele in Alzheimer's disease and vascular dementia. Dementia. 5:1994;240-242.
28. Noguchi S, Murakami K, Yamada N. Apolipoprotein E genotype and Alzheimer's disease. Lancet. 342:1993;737.
29. Pedro-Botet J, Sentui M, Nogues X, et al. Lipoprotein and apolipoprotein profile in men with ischemic stroke. Role of lipoprotein(a), triglyceride-rich lipoproteins, and apolipoprotein E polymorphism. Stroke. 23:1992;1556-1562.
30. Saunders AM, Roses AD. Apolipoprotein E4 allele frequency, ischemic cerebrovascular disease, and Alzheimer's disease. Stroke. 24:1993;1416.
31. Kosunen O, Talasniemi S, Lehtovirta M, et al. Relation of coronary atherosclerosis and apolipoprotein E genotypes in Alzheimer patients. Stroke. 26:1995;743-748.
32. Schmechel DE, Saunders AM, Strittmatter WJ, et al. Increased amyloid B-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer's disease. Proc Natl Acad Sci USA. 90:1993;9649-9653.
33. Rebeck GW, Reiter JS, Strickland DK, Hyman BT. Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron. 11:1993;575-580.
34. Pancharuniti N, Lewish CA, Sauberlich HE, et al. Plasma homocyst(e)ine, folate, and 12 concentrations and risk for early onset coronary artery disease. Am J Clin Nutr. 59:1994;940-948.
35. Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA. 268:1992;877-881.
36. LaRue A, Koehler KM, Wayne SJ, et al. Nutritional status and cognitive functioning in a normally aging sample: a 6 y reassessment. Am J Clin Nutr. 65:1997;20-29.
37. Gale CR, Martyn CN, Cooper C. Cognitive impairment and mortality in a cohort of elderly people. Br Med J. 312:1996;608-611.
38. Kondo K, Niino M, Shido K. A case-control study of Alzheimer's disease in Japan - significance of life-styles. Dementia. 5:1994;314-326.
39. Meyer JS, Rogers RL, Mortel KF. Prospective analysis of long-term control of mild hypertension on cerebral blood flow. Stroke. 16:1985;985-989.
40. Nobili F, Rodriguez G, Marenco S, et al. Regional cerebral blood flow in chronic hypertension. Stroke. 24:1993;1148-1153.
41. Meyer JS, Judd BW, Tawakina T, Rogers RL, Mortel KF. Improved cognition after control of risk factors for multi-infarct dementia. JAMA. 256:1986;2203-2209.
42. Irie K, Yamaguchi T, Minematsu K, Omae T. The J-curve phenomenon in stroke recurrence. Stroke. 24:1993;1844-1849.
43. Shinohara Y. Management of blood pressure in acute and chronic cerebrovascular disease from the view point of cerebral blood flow. J Stroke Cerebrovasc Dis. 4:1994;S80-S83.
44. Sadoshima S, Fujii K, Ooboshi H, Ibayashi S, Fujishima M. Angiotensin converting enzyme inhibitors attenuate ischemic brain metabolism in hypertensive rats. Stroke. 24:1993;1561-1567.
45. Arregui A, Perry EK, Rossor M, Tomlinson BE. Angiotensin converting enzyme in Alzheimer's disease: increased activity in caudate nucleus and cortical areas. J Neurochem. 38:1982;1490-1492.
46. Paganini-Hill A, Ross RK, Henderson BE. Postmenopausal oestrogen therapy and stroke: a prospective study. Br Med J. 297:1988;519-522.
47. Falkeborn M, Persson I, Terent A, et al. Hormone replacement therapy and the risk of stroke: follow-up of a population-based cohort in Sweden. Arch Intern Med. 153:1993;1201-1209.
48. Shaw TG, Mortel KF, Meyer JS, et al. Cerebral blood flow changes in benign aging and cerebrovascular disease. Neurology. 34:1984;855-862.
49. Marmorston J. Effect of estrogen treatment in cerebrovascular disease. Millikan C, Siekert R, Whisnant J. Cerebral Vascular Diseases. 1965;214-220 Greene & Stratton, New York.
50. Funk JL, Mortel KKF, Meyer JS. Effects of estrogen replacement therapy on cerebral perfusion and cognition among postmenopausal women. Dementia. 2:1991;268-272.
51. Gilligan DM, Quyyumi AA, Cannon RO III. Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation. 89:1994;2545-2551.
52. Polderman KH, Stehouwer CD, van Kamp GJ, et al. Influence of sex hormones on plasma endothelin levels. Ann Intern Med. 118:1993;429-432.
53. Van Buren G, Yang D, Clark KE. Estrogen-induced uterine vasodilatation is antagonized by L-nitroarginine methylester, an inhibitor of nitric oxide synthesis. Am J Obstet Gynecol. 167:1992;828-833.
54. Gangar KF, Vyas S, Whitehead M, et al. Pulsatility index in internal carotid artery in relation of transdermal oestradiol and time since menopause. Lancet. 338:1991;839-842.
55. Ohkura T, Eshima Y, Isse K, et al. Estrogen increases cerebral and cerebellar blood flows in postmenopausal women. Menopause. 2:1994;13-18.
56. Schneider R, Ringelstein EB, Zeumer H, et al. The role of plasma hyperviscosity in subcortical arteriosclerotic encephalopathy (Binswanger's disease). J Neurol. 234:1987;67-73.
57. Meyer JS, Rogers RL, McClintic K, Mortel KF, Lotfi J. Randomized clinical trial of daily aspirin therapy in multi-infarct dementia. J Am Geriatr Soc. 37:1989;549-555.
58. Black RS, Barclay LL, Nolan KA, Thaler HT, Hardiman ST, Blass JP. Pentoxifylline in cerebrovascular dementia. J Am Geriatr Soc. 40:1992;237-244.
59. Swan GE, LaRue A, Carmelli D, et al. Decline in cognitive performance in aging twin. Arch Neurol. 49:1992;476-81.
60. Wada T, Matsubayashi K, Okumiya K, et al. Serum cholesterol levels and cognitive function assessed by P300 latencies in an older population living in the community. J Amer Ger Soc. 45:1997;122-123.
61. Handelman GE, Boyles JK, Weisgraber KH, et al. Effects of apoliprotein E, very low density lipoproteins, and cholesterol on the extension of neurites by rabbit dorsal root ganglion neurons in vitro. J Lipid Res. 33:1992;1677.
62. Mason RP, Shoemaker WJ, Shajenko L, et al. Evidence for changes in the Alzheimer's disease brain cortical membrane structure mediated by cholesterol. Neurobiol Aging. 13:1992;413-419.
63. Mason RP, Herbette LG, Silverman DI. Can altering serum cholesterol affect neurologic function? J Mol Cell Cardiol. 23:1991;1339-1342.
64. Wurtman RJ. Dietary treatments that affect brain neurotransmitters: effects of calorie and nutrient intake. Ann NY Acad Sci. 499:1987;189-190.
65. Muldoon MF, Kaplan JR, Manuck SB, Mann JJ. Effects of dietary fat on central nervous system serotonergic activity. Psychosom Med. 53:1991;216.
66. Kaplan JR, Manuck SB, Shively C. The effects of fat and cholesterol on social behavior in monkeys. Psychosomat Med. 53:1991;634-642.
67. Engelberg H. Low serum cholesterol and suicide. Lancet. 339:1992;727-729.
68. Morgan RE, Palinkas LA, Barrett-Connor EL, Wingard DL. Plasma cholesterol and depressive symptoms in old men. Lancet. 341:1993;75-79.
69. Virkkunen M, Penttinen H. Serum cholesterol in aggressive conduct disorder. Biol Psych. 190:1984;435-439.
70. Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. Br Med J. 301:1990;309-314.
71. Roth T, Richardson GR, Sullivan JP, et al. Comparative effects of pravastatin and lovastatin on nighttime sleep and daytime performance. Clin Cardiol. 15:1992;426-432.
72. Santanello NC, Barber BL, Applegate WB, et al. Effect of pharmacologic lipid lowering on health-related quality of life in older persons: results from the Cholesterol Reduction in Seniors Program (CRISP) pilot study. J Am Ger Soc. 45:1997;8-14.
73. Kronmal RA, Cain KC, Ye Z, Omen GS. Total serum cholesterol levels and mortality risk as a function of age. Arch Internal Med. 153:1993;1065-1073.
74. Straessen J, Amery A, Birkenhager W, Bulpitt C, Clement D, de Leeuw P, Deruyttere M, De Schaepdryver A, Dollery C, Fagard R, et al. Is a high serum cholesterol level associated with longer survival in elderly hypertensives? J Hypertens. 8:1990;755-761.
75. Forretta B, Tortrat D, Wolmark Y. Cholesterol as risk factor for mortality in elderly women. Lancet. 1:1989;868-870.
76. Denke MA, Grundy SM. Hypercholesterolemia in elderly persons: resolving the treatment dilemma. Ann Int Med. 112:1990;780-792.
77. Breitner JCS, Welsh KA, Helms MJ, Gaskell PC, et al. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging. 16:1995;523-530.
78. Stavart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer's disease and duration of NSAID use. Neurology. 48:1997;626-632.
79. Andersen K, Launer LJ, Oh A, et al. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease - the Rotterdam Study. Neurology. 45:1995;1441-1445.
80. Anonymous. Canadian Study of Health and Aging: risk factors for Alzheimer's disease in Canada. Neurology. 44:1994;2073-2080.
81. Rich JB, Rasmusson DX, Folstein MF, et al. Nonsteroidal anti-inflammatory drugs in Alzheimer's diseae. Neurology. 45:1995;51-55.
82. Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethicin in Alzheimer's disease. Neurology. 43:1993;1609-1611.
83. Breitner JCS. The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer's disease. Ann Rev Med. 47:1996;401-411.
84. McGeer PL, McGeer EG. Chronic inflammatory mechanisms of the brain: implications for the treatment of Alzheimer's disease. Dementia. 9:1995;111-123.
85. Phillips S, Sherwin BB. Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology. 17:1991;485-495.
86. Singh M, Meyer EM, Millard WJ, Simpkins JW. Ovarian steroid deprivation results in reversible learning impairment and compromised cholinergic function in female Sprague-Dawley rats. Brain Res. 644:1994;305-312.
87. Caldwell BM. An evaluation of psychological effects of sex hormone administration in aged women. J Gerontol. 9:1954;168-174.
88. Kantor HI, Michael CM, Shore H. Estrogen for older women. Am J Obstet Gynecol. 116:1973;115-118.
89. Fillit H, Weinreb H, Cholst I, et al. Observations in a preliminary open trial of estradiol therapy for senile dementia (Alzheimer's type). Psychoneuroendocrinology. 11:1986;337-345.
90. Honjo H, Ogino Y, Naitoh K, et al. In vivo effects by estrone sulfate on the central nervous system - senile dementia (Alzheimer's type). J Steroid Biochem Mol Biol. 34:1989;521-525.
91. Ohkura T, Isse K, Akazawa K, et al. Long-term estrogen replacement therapy in female patients with dementia of the Alzheimer type: 7 case reports. Dementia. 6:1995;99-107.
92. Woolley CS, McEwen BS. Role of estradiol and progesterone in regulation of hippocampal dendritic spine density during estues cycle in the rat. J Comp Neurol. 336:1993;298-306.
93. Sheikh JI, Yesavage JA. Geriatric Depression Scale (GDS). Recent evidence and development of a shorter version. Clin Gerontol. 5:1986;165-173.
94. Berg L, Hughes CP, Cohen LA, et al. Mild senile dementia of the Alzheimer type: research diagnostic criteria, recruitment, and description of a study population. J Neurol Neurosurg Psychiatr. 45:1982;962-968.
95. Guy W. ECDEU Assessment Manual for Psychopharmacology. 1976;218-222 US Department of Health, Education, and Welfare, National Institutes of Mental Health, Rockville MD.
96. Sonnenberg JVN, Krey VN, Christakos LL. 1,25-dihydroxyvitamin D3 treatment results in increased choline acetyltransferase activity in specific brain nuclei. Endocrinology. 118:1986;1433-1439.
97. Briton RD, Proffitt P, Ran J, Luu R. Equilin, a principal component of the estrogen replacement therapy, Premarin, increases the growth of cortical neurons via an NMDA receptor dependent mechanisms. Exp Neurol. 1997; in press.